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Abstract
Antibiotic resistance is one of the most significant challenges
facing the medical community today. In response, the Centers
for Disease Control and Prevention (CDC) created a list of the
greatest antibiotic resistance threats, a number of which are
gram-positive bacteria. The cell wall of these organisms has
long been a favored target of antibiotic therapies, but the development of numerous resistance mechanisms has led to
widespread resistance against nearly all major antibiotic
compounds on the market. The medical community is faced
with the task of developing better antibiotic compounds that
preclude the spread of bacterial resistance and also increasing the screening of natural antimicrobials from organisms
not readily cultured in the laboratory. The iChip is a novel in
situ cultivation device that allows researchers to grow cultures of bacterial species that could not otherwise be cultured
in a laboratory setting. This technology has already led to the
discovery of several promising novel antimicrobial compounds, including teixobactin. This depsipeptide has excellent
activity in vitro against gram-positive organisms including
Clostridium difficille, Bacillus anthracis, Enterococcus strains
(including vancomycin resistant enterococci), Mycobacterium
tuberculosis and Staphylococcus aureus. Pharmacists have a
significant impact in the education of patients receiving antibiotic therapy about the issue of drug resistance and how
alternative courses of treatment may be needed if antibiotic
therapy is unsuccessful.
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An Overview of Antibiotic Resistance
Antibiotic resistance is one of the most significant challenges
facing the medical community today. Not only are bacteria
adapting at an increasingly rapid rate, but researchers are
developing new antibiotics at the slowest rate since the advent of modern antimicrobials.1 Governments around the
world have realized that antibiotic resistance is a serious
threat, and in the United States numerous federal and state
agencies are now releasing guidelines and plans on how to
face this issue. It is generally agreed upon that in order to
effectively combat resistance, the medical profession must:
1) prevent infections and further spread of resistance,
2) track resistant bacteria, 3) improve the use of current antibiotics, 4) promote the development of new antibiotics and
diagnostic tests for resistant bacteria and 5) promote better
public education about proper antibiotic use and antibiotic
resistance.1,2
According to the Centers for Disease Control and Prevention
(CDC), over 2 million illnesses and 23,000 deaths occur each
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year in the United States due to antibiotic resistant organisms.1 These infections are also vastly more difficult and
expensive to treat. Estimates of the economic impact of antibiotic resistance range up to $20 billion, with an even higher
cost in lost productivity. Antibiotics in general are also responsible for nearly one in five emergency department visits
due to adverse drug events (AD Es) and are the leading cause
of adolescent emergency department visits for ADEs. The
CDC created a list of the greatest antibiotic resistance threats
categorized as urgent, serious and concerning. Gram-positive
Clostridium difficile and carbapenem-resistant enterobacteriaceae (CRE) are two of the three "urgent" threats, and there
are also a significant number of gram-positive species in the
lower categories.
A brief examination of the history of antibiotic development,
as compared to antibiotic resistance, helps illustrate the increasing difficulty of not only developing new antimicrobial
agents but also fostering proper and effective use of currently available compounds.1 Several years before the widespread use of penicillin in 1943, there were already known
isolates of resistant Staphylococcus species. With the development of additional 13-lactams and tetracyclines, bacterial
species resistant to these compounds also rapidly emerged.
As the 20th century closed, every major antimicrobial compound had known resistant isolates. The first decade of the
21st century has seen relatively few new antibiotics introduced to market, yet even these compounds are already associated with resistant species.
Common Cell Wall Associated Mechanisms of Resistance
in Gram-Positive Bacterial Species
The bacterial cell wall and its synthesis are common targets
among natural and synthetic antibacterial compounds. This
section discusses numerous drug targets associated with cell
wall synthesis as well as resistance mechanisms.
The oldest and largest class of modern antibiotics are the
13-lactams, some examples of which include the penicillins,
cephalosporins and carbapenems.3 Transpeptidases involved
in cell wall synthesis act as penicillin binding proteins (PBPs)
due to their affinity for the 13-lactam ring. By mimicking endogenous precursors, 13-lactams inhibit transpeptidase activity. However, bacterial species that produce enzymes capable
of hydrolyzing the 13-lactam ring are able to inactivate the
drug. 13-lactamase associated resistance is a leading cause of
resistance to the 13-lactams.4 Another common cause of
13-lactam resistance is the protein PBP2a. Bacteria that acquire and express the mecA gene are able to synthesize
PBP2a, which then crosslinks peptidoglycan (PG) when the
normal transpeptidase PBPs are inactivated by 13-lactams.s
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Figure 1. Isolation Chip (iChip) Design.
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(a & b) sample illustration of how the iChip is placed in suspension to capture single cells per each through-hole; (c) two outer plates are fastened to the
center plate in the assembly of the iChip. Adapted from: Ling LL, Schneider T, Peoples Aj, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015 Jan 22;517(7535):455-9. Used with permission of the authors.

Wall teichoic acid (WTA) and its synthesizing enzyme Taro
are also viable targets for antibiotic compounds.s It is hypothesized that WT As play a role in stability of the cell wall
during division. Inhibition of WT A synthesis via gene deletion or pharmacological intervention results in defective and
inefficient bacterial cell division. Furthermore, Campbell et
al. demonstrated a "synthetic lethality" when they combined
an inhibitor of Taro with ~-lactam antibiotics. In one of the
experiments, investigators observed that methicillin resistant Staphylococcus aureus (MRSA) strains treated with
tunicamycin developed a significant sensitivity to a number
of ~-lactam antibiotics. However, this synergistic effect did
not carry over to other classes. A possible reason for this specific synergism is that inhibition of WT As results in misplacement of PBP targets of the ~-lactam class, allowing these
drugs to overcome resistance mechanisms.
Two additional targets for inhibiting cell wall synthesis are
Lipid II and Lipid Ill. These compounds are associated with
the movement of PG building blocks across the cell membrane.3,6 Lipid II is a precursor of PG that is transported
across the cell membrane by flippase-type transporters.7,B
Once outside the cell, Lipid II is incorporated into the cell
wall. Glycopeptide antibiotics, such as vancomycin and
teicoplanin, are known to inhibit Lipid II. Despite the large
number of naturally occurring antimicrobials that favor this
target, vancomycin resistant organisms are becoming increasingly common. 1 This is due to the presence of the vanA-
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type resistance operon which changes the terminal amino
acids on Lipid II from D-alanine-D-alanine to D-alanine-Dlactate.3 This change adversely impacts the binding affinity
of vancomycin for Lipid II, resulting in resistance. Lipid III is
involved in WT A synthesis. As mentioned previously, WTAs
are not essential to cell survival, however, inhibition of WT A
synthesis at Lipid III can lead to the buildup of toxic intermediates as well as autolysin mediated degradation of PG.S.6

The Need for Better Antibiotics and Techniques of Discovery
As the above sections highlight, there are numerous and diverse pathways by which antibiotic drugs target grampositive bacteria. However, these organisms have developed
highly efficient means of evading both natural and synthetic
antimicrobial compounds, and this capability threatens to
render the vast majority of current antibiotics useless. Moving forward, the medical community has several options:
develop better antibiotic compounds that preclude the development of bacterial resistance and/or find ways to increase
the screening of natural antimicrobials -from organisms not
readily cultured in the laboratory.1.6
One of the greatest limitations in modern antimicrobial discovery is that traditional, yet current cultivation methodologies, such as petri dish cultivation, are unable to effectively
cultivate certain microbial phyla with known or suspected
cultivable representatives. As a result, both the potential to
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Table 1. Bactericidal Activity ofTeixobactin.9
Organism and Genotype

Teixobactin MIC (µg/mL)

Staphylococcus aureus (MSSA)

0.25

Staphylococcus aureus (MRSA)

0.25

Enterococcus faecalis (VRE)

0.5

Bacillus anthracis

::; 0.06

Clostridium difficile

0.005

Haemophilus influenzae

4

Escherichia coli

25

Escherichia coli (asmB1)

2.5

Pseudomonas aeruginosa

> 32

Klebsiella pneumoniae

> 32

MSSA = methicillin-sensitive Staphylococcus aureus; MRSA = i:nethicillin-resistant Staphylococcus aureus; VRE = vancomycin-resistant
Enterococci; asm81 = a cell membrane assembly suppressor mutation. Minimum inhibitory concentration (MIC) values were determined
by broth microdilution. Adapted from : Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015 Jan 22;517(7535):455-9. Used with permission of the authors.

screen for and culture new anti-infective agents is limited in
the drug discovery process.9 In 2009, however, the development and introduction of a novel in situ cultivation method,
referred to as an isolation chip (iChip), demonstrated a
promising capacity to cultivate environmental microorganisms that were formerly considered "uncultivable."
Specifically, the iChip (Figure 1) is an assembly of three
sealed hydrophobic plastic polyoxymethylene plates (one
central plate and two outer panels), with each containing
several hundred "through-holes," which permit the capture
of single microbial cells when suspended in an agar-based
liquid medium. On each side of the central plate and between
each of the outer panels are two 47-mm polycarbonate membranes which prohibit the migration of single cells captured
in the through-holes. Collectively, these technological features enable the isolation of monospecific cultures, particularly of microbial phyla that could not be previously cultured
in conventional methods such as petri dishes.
Isolation ofTeixobactin Using iChip Cultivation
The ability of iChip to isolate formerly uncultivable microorganisms indicates its promising potential to expand the drug
discovery effort of anti-infective agents, especially those that
may be able to combat the problem of drug resistance among
current anti-infective agents available in the United States'
pharmaceutical market. In fact, in January 2015, Ling et al. of

NovoBiotic Pharmaceuticals in Cambridge, Massachusetts,
utilized iChip cultivation among 10,000 different microbial
isolates and identified a new antibiotic-teixobactin-that
demonstrated notable bactericidal activity against commonly
known drug-resistant microbes, including Staphylococcus
aureus, difficult-to-treat enterococci, Mycobacterium tuberculosis, Clostridium difficile and Bacillus anthracis (Table 1).9
Teixobactin (Figure 2), an unusual depsipeptide which contains enduracididine, methylphenylalanine and four
D-amino groups, is proposed to inhibit bacterial cell wall synthesis in gram-positive microbes by binding to Lipid II and
Lipid III, precursors of peptidoglycan and teichoic acid, respectively.
Therapeutic Implications of Teixobactin in Combating
Antibiotic Resistance
The bactericidal activity and undeveloped resistance of teixobactin gives the compound an edge over anti-infective agents
displaying resistance profiles and bacteriostatic properties.
Researchers found teixobactin had excellent activity in vitro
against gram-positive organisms including drug-resistant
strains. 6 Data results showed the compound had exceptional
activity against Clostridium difficille and Bacillus anthracis,
and also displayed excellent activity against Enterococcus
strains, Mycobacterium tuberculosis and Staphylococcus aureus. The advantage of teixobactin compared to current anti-
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Figure 2. Teixobactin Predicted Structure and Biosynthetic Gene Cluster.
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Adapted from: Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable
resistance. Nature. 2015 Jan 22;517(7535):455-9. Used with permission of the authors.

infective agents is based on the inability of bacteria to develop resistance. Teixobactin's major targets, Lipid II and Lipid
III, are a new way to inhibit cell wall biosynthesis, which is
why bacteria have not been able to show resistance yet. Researchers were unable to obtain mutants of Staphylococcus
aureus or Myobacterium tuberculosis resistant to teixobactin, even when plating on media with a low dose (four times
Minimum Inhibitory Concentration) of the compound. Table
2 shows a summary of common antibiotic drugs, their targets
and mechanisms of resistance. Although the table is not comprehensive, it displays the mechanisms of resistance relative
to drug targets. It also shows teixobactin targets a slightly
different part of the bacterial cell wall than what has been
targeted in the past by other anti-infective agents. Unfortunately, teixobactin is mostly ineffective against gramnegative bacteria because the compound does not target the
components in the gram-negative wall. The bacteria from
which teixobactin was isolated, Eleftheria terrae (betaproteobacteria), is a gram-negative bacteria, and the organism would not survive if it inhibited its own cell wall. Animal
studies establishing safety and efficacy data are the next step
in pushing teixobactin toward approval by the U.S. Food and
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Drug Administration (FDA). Researchers have shown that
teixobactin had no toxicity against mammalian cells at
100 µg/mL (the highest dose tested) in vitro. Teixobactin
showed no hemolytic activity, did not bind DNA, and was
tested in vivo in mice infected with Streptococcus pneumonia; it was shown to be highly efficacious because it caused a
6 log10 reduction of colony forming units in the lungs.

The Role of the Pharmacist
The role of pharmacists is to prevent antibiotic resistance
from progressing by thoroughly explaining antibiotic drug
regimens to patients and educating patients on the importance of finishing a regimen although symptoms may
have subsided. Furthermore, pharmacists can educate patients on antibiotic resistance in the community and can help
patients understand that antibiotics do not work against viral infections. Lastly, pharmacists can stay informed on the
latest news for antibiotic discovery so that they understand
the indications and mechanisms of new antibiotic compounds for when these drugs are placed on the shelf in the
pharmacy for the first time. This will allow pharmacists to
give physicians and other health care professionals with pre-
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3,5,6

Drug Class

Select Compounds

Drug Targets / Mechanism of Action

Common Resistance Mechanisms

S-lactams

penicillins, cephalosporins, carbapenems

PBPs / inhibition of transpeptidases

B-lactamase, PBP2a activity

Sugar
substrate
analogue

tunicamycin

WYA synthesis, Taro/ decreased
efficiency of cell division, increased
susceptibility to B-Iactams

"Synthetic lethality" unique to
combination Taro inhibitor and
15-lactam. Not effective with other
classes.

Glycopeptides

vancomycin, teicoplanin

Lipid II / incomplete cell wall
biosynthesis

Alteration of Lipid II terminal
amino acids

Novel
depsipeptide

teixobactin

Lipid II, Lipid III /incomplete cell wall
biosynthesis, toxic intermediates of
WTA synthesis

None yet observed

scribing abilities expert advice in choosing the best antibiotic
regimen possible for patients.

8.

9.

Conclusion
Due to the fact that bacteria are becoming more resistant to
antibiotic compounds at an increasing rate, it is vital for the
well being of patients presenting with infections to discover
new antibiotics that can help better fight off these resistant
pathogenic organisms. These organisms have developed
highly efficient means of evading both natural and synthetic
antimicrobial compounds, and this ability threatens to make
the vast majority of current antibiotics useless. The development of iChip as a novel in situ cultivation method for environmental microorganisms that were once thought to be uncultivable demonstrates a promising capacity to discover
antibiotic compounds that can be used to combat highly resistant bacterial infections.
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